Racial disparities in the outcomes of transitional cell carcinoma of the bladder: A population-based analysis.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 577-577
Author(s):  
Firas Baidoun ◽  
Inas A. Ruhban ◽  
Anas M. Saad ◽  
Mohamed M. Gad ◽  
Khalid Jazieh ◽  
...  
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Racial Disparities ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Stage Iv ◽  
The United States ◽  
Pacific Islanders ◽  
The Us

577 Background: Bladder cancer is the most common type of genitourinary malignancy and is the fourth most common cancer in men in the US. Transitional cell carcinoma (TCC) of the bladder accounts for most bladder cancer cases. Previous studies have observed racial disparities in the prognosis between white and black populations with very little mentioned about other ethnicities and race groups that are part of the United States population. We hereby, present a detailed and comprehensive analysis of racial disparities in TCC survival in the US. Methods: Using the data from surveillance Epidemiology and End results (SEER) database, we identified patients with TCC between 1992 and 2015. We used multivariable covariate-adjusted Cox models to analyze the overall and TCC-specific survival of patients according to their race. Results: We evaluated 176,388 patients with TCC and after we adjusted for age, sex, race, stage, grade, and undergoing cancer-targeted surgery, we found that Asians/Pacific Islanders and Hispanics had a better overall survival when compared to whites (HR= 0.792, 95% CI [0.761-0.824], P<.001 and HR = 0.941, 95% CI [0.909-0.974], P = .001, respectively). Asians/Pacific Islanders also showed better TCC specific survival (HR = 0.843, 95% CI [0.759-0.894], P<.001). Blacks had worse overall survival and TCC-specific survival (HR =1.221, 95% CI [1.181-1.262], P <.001 and HR =1.325, 95% CI [1.268- 1.384], P <.001, respectively). When stage IV TCC was analyzed separately, only Hispanics showed better overall and TCC specific survival when compared to whites (HR = 0.896, 95% CI [0.806-0.997], P = 0.044 and HR = 0.891, 95% CI [0.797-0.996], P = 0.42). Conclusions: Asians/Pacific Islanders have better overall and TCC-specific outcome while blacks have the worst outcome compared to whites. Hispanics have better overall and cancer specific survival in stage IV TCC. These disparities likely related to different and complex factors from lifestyle and chemical exposure to genetic factors. Further studies can help us more in understanding and approaching this malignancy in different race groups.

405: Previous History of Bladder Cancer is an Independent Prognostic Factor for Upper Tract Transitional Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 135-135
Author(s):  
Eiji Kikuchi ◽  
Akira Miyajima ◽  
Ken Nakagawa ◽  
Mototsugu Oya ◽  
Takashi Ohigashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Previous History ◽  
Independent Prognostic Factor ◽  
Upper Tract ◽  
History Of

scholarly journals Paraneoplastic production of heparin-like anticoagulant in a patient with metastatic transitional cell carcinoma

2013 ◽  
Vol 3 (5) ◽  
pp. 61 ◽  
Author(s):  
Kelly N. Fahl ◽  
Stephen A. Poon ◽  
Ketan K. Badani ◽  
Mitchell C. Benson
Keyword(s):  
Bladder Cancer ◽  
Breast Carcinoma ◽  
Liver Failure ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Hematological Malignancies ◽  
Transitional Cell ◽  
Carcinoma Breast ◽  
Severe Coagulopathy

It has been reported that patients with bladder cancer have widelyvarying paraneoplastic consequences, including metabolic, dermatologic,myopathic and neurologic disturbances. We report a case of a52-year-old man with advanced transitional cell carcinoma and livermetastases, who developed a severe coagulopathy following roboticradical cystoprostatectomy due to circulating heparin-like substancesprior to onset of liver failure. Heparin-like anticoagulant production isa rare paraneoplastic effect documented in concert with transitionalcell carcinoma, breast carcinoma and hematological malignancies.

Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy

2003 ◽  
Vol 21 (12) ◽  
pp. 2247-2253 ◽  
Author(s):  
Lance C. Pagliaro ◽  
Afsaneh Keyhani ◽  
Dallas Williams ◽  
Denise Woods ◽  
Baoshun Liu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Bladder Cancer ◽  
Gene Transfer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Locally Advanced ◽  
Transitional Cell ◽  
P53 Gene ◽  
Advanced Bladder Cancer ◽  
Intravesical Instillations

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (1010 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

scholarly journals Urothelial bladder carcinoma with major clinical presentation as overactive bladder, without hematuria: case report and literature review

2018 ◽  
Vol 7 (10) ◽  
pp. 4292
Author(s):  
Alexander de J. Rafaelano M. ◽  
Junior J. Araiza Navarro ◽  
María Isabel Tolentino Sosa ◽  
Fernando López Reyes ◽  
Marlene De la Peña Gutiérrez
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
The United States ◽  
Transitional Epithelium ◽  
Common Symptom ◽  
Macroscopic Hematuria ◽  
Adjacent Structures

The urothelial carcinoma is the most common type of bladder cancer, comprising approximately 90% of cases in the United States. The most common symptom of bladder cancer is macroscopic hematuria, increased urinary frequency, urgency, or irritative symptoms may occur. Generally, occurs in elderly people, about 9 out of 10 people are over 55 years old, with the average age at diagnosis of 73 years. Males are more likely than women to have this neoplasm with a probability of 1 in 27 (for women the probability is 1 in 89). Most bladder cancers begin in the inner layer, also called the urothelium or transitional epithelium. As it advances, it invades the layers of the bladder and can invade adjacent structures, often metastasizing to distant lymph nodes, bones, lungs or the liver. Among the cancers that originate in the bladder authors have: Urothelial carcinoma (transitional cell carcinoma), squamous cell carcinoma, adenocarcinoma, small cell carcinoma, sarcoma. Hematuria occurs in the majority of patients with urothelial carcinoma. Symptoms such as dysuria, frequency, urgency and pain may also occur, or it may also be asymptomatic.  In this case report, an atypical presentation of bladder cancer is shown, simulating the symptomatology of a Hyperactive Bladder Syndrome.

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer

Urology ◽  
2003 ◽  
Vol 61 (3) ◽  
pp. 539-543 ◽  
Author(s):  
Scott M Gilbert ◽  
Robert W Veltri ◽  
Alex Sawczuk ◽  
Ahmad Shabsigh ◽  
David R Knowles ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
History Of ◽  
Carcinoma Of The Bladder

Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma

2004 ◽  
Vol 22 (6) ◽  
pp. 1007-1013 ◽  
Author(s):  
Sunanda J. Chatterjee ◽  
Ram Datar ◽  
David Youssefzadeh ◽  
Ben George ◽  
Peter J. Goebell ◽  
...  
Keyword(s):  
Overall Survival ◽  
Lymph Node ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Combined Effects ◽  
Wild Type ◽  
Bladder Transitional Cell Carcinoma ◽  
Time To Recurrence ◽  
Group I

Purpose To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node–negative, 117 patients; lymph node–positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0% to 10%) or altered (> 10%); p21 was scored as wild-type (>10%) or altered (< 10%); and pRb status was considered wild-type (1% to 50%) or altered (0% or > 50%). Results As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23%, 32%, 57%, and 93%, respectively (log-rank P < .001), and the 5-year survival rates were 70%, 58%, 33%, and 8%, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.

Sign in / Sign up

Export Citation Format

Share Document